ARCHIVES

ASCO Annual Meeting: PARP Inhibitors Show Promise Against Breast Cancer In Small Phase II Studies

This article is from The Cancer Letter archive.

Vol. 35 No. 22 | June 5, 2009

Download PDF Visit The Full Archive

Related Articles

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

November 20, 1992

In Brief: Top Priority: Keep Rauscher; Pay Raise Bill No Moving; Miller, Holland Head AACR, ASCO

May 21, 1976

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001

Faulty Estimates Led NCI To Overstate Black-White Cancer Disparity In Atlanta

September 20, 2002

Duke Officials Decline To Provide Details Of Probe

July 23, 2010

In Brief: NCI Planning 50th Anniversary In 1987, Seeks Information On Alumni For Observance In May

January 24, 1986